Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

LGBTQI' Defined: An Introduction to Understanding and Caring for the Queer Community
Gallego, Joseph D., Knudsen, John Chr.

MedEdPORTAL | September 3, 2015 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.10189 Get It

Hydrolysable core crosslinked particles for receptor-mediated pH-sensitive anticancer drug delivery
Liu, Xifeng , Waletzki, Brian E., Mamo, Tewodros , Yaszemski, Michael J. , Lu, Lichun , Miller, A. Lee , Mamo, Tewodros K, Miller, Alan Lee

New Journal of Chemistry | September 3, 2015 | Volume: 39 | Issue: 11 | Pages: 8840-8847

10.1039/c5nj01404b | PMID 27134519 Get It

An extracellular stable micelle with a folate conjugated surface, a crosslinked core and pH-sensitive hydrolysable bonds was developed for cancer targeted drug delivery.
Heritability of young‐ and old‐onset ischaemic stroke
Bluher, Andrew E. , Devan, William J., Holliday, E. G., Nalls, Mike A. , Parolo, Silvia , Bione, Silvia , Giese, Anne‐Katrin , Boncoraglio, Giorgio B. , Maguire, Jane , Müller‐Nurasyid, Martina , Gieger, Christian , Rolfs, A., Kittner, Steven J. , Mitchell, Braxton D. , O’Connell, Jeff, Holliday, E. G., Meschia, James F. , Rosand, Jonathan M. , Cheng, Y.‐C., Mitchell, Braxton D

European Journal of Neurology | September 3, 2015 | Volume: 22 | Issue: 11 | Pages: 1488-1491

10.1111/ene.12827 | PMID 26333310 Get It

Background and purposeAlthough the genetic contribution to stroke risk is well known, it remains unclear if young‐onset stroke has a stronger genetic contribution than old‐onset stroke. This study aims to compare the heritability of ischaemic stroke risk between young and old, using common genetic variants from whole‐genome array data in population‐based samples.MethodsThis analysis included 4050 ischaemic stroke cases and 5765 controls from six study populations of European ancestry; 47% of cases were young‐onset stroke (age < 55 years). To quantify the heritability for stroke risk in these unrelated individuals, the pairwise genetic relatedness was estimated between individuals based on their whole‐genome array data using a mixed linear model. Heritability was estimated separately for young‐onset stroke and old‐onset stroke (age ≥ 55 years).ResultsHeritabilities for young‐onset stroke and old‐onset stroke were estimated at 42% (±8%, P < 0.001) and 34% (±10%, P < 0.001), respectively.ConclusionsOur data suggest that the genetic contribution to the risk of stroke may be higher in young‐onset ischaemic stroke, although the difference was not statistically significant.
Sorting nexin 9 differentiates ligand-activated Smad3 from Smad2 for nuclear import and transforming growth factor β signaling
Wilkes, Mark C. , Repellin, Claire E. , Kang, Jeong Han , Andrianifahanana, Mahefatiana, Yin, Xueqian , Leof, Edward B.

Molecular Biology of the Cell | September 3, 2015 | Volume: 26 | Issue: 21 | Pages: 3879-3891

10.1091/mbc.e15-07-0545 | PMID 26337383 Get It

Transforming growth factor β (TGFβ) is a pleiotropic protein secreted from essentially all cell types and primary tissues. While TGFβ’s actions reflect the activity of a number of signaling networks, the primary mediator of TGFβ responses are the Smad proteins. Following receptor activation, these cytoplasmic proteins form hetero-oligomeric complexes that translocate to the nucleus and affect gene transcription. Here, through biological, biochemical, and immunofluorescence approaches, sorting nexin 9 (SNX9) is identified as being required for Smad3-dependent responses. SNX9 interacts with phosphorylated (p) Smad3 independent of Smad2 or Smad4 and promotes more rapid nuclear delivery than that observed independent of ligand. Although SNX9 does not bind nucleoporins Nup153 or Nup214 or some β importins (Imp7 or Impβ), it mediates the association of pSmad3 with Imp8 and the nuclear membrane. This facilitates nuclear translocation of pSmad3 but not SNX9.
Paraspinal neurofibromas and hypertrophic neuropathy in Noonan syndrome with multiple lentigines
Conboy, Erin , Dhamija, Radhika , Wang, Margaret , Xie, Jing , Dyck, P. James B. , Bridges, Alina G. , Spinner, Robert J. , Clayton, Amy C., Watson, Robert E. , Messiaen, Ludwine , Babovic‐Vuksanovic, Dusica , Dyck, P James, Dhamija, Radhika

Journal of Medical Genetics | September 2, 2015 | Volume: 53 | Issue: 2 | Pages: 123-126

10.1136/jmedgenet-2015-103177 | PMID 26337637 Get It

Background Noonan syndrome with multiple lentigines (NSML), formerly known as LEOPARD syndrome, is an autosomal-dominant disorder characterised by lentigines, EKG abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, growth retardation and deafness. There is significant clinical overlap between NSML and other disorders that result from dysregulated rat sarcoma/mitogen-activated protein kinase pathway (RASopathies). Except for neurofibromatosis type 1, other RASopathies are not known to be typically associated with neurogenic tumours. Methods and results We evaluated patients from three families with pigmentary skin lesions, progressive neuropathy, enlarged nerves, massive burden of paraspinal tumours (neurofibroma was confirmed in one patient) and a clinical diagnosis of NSML. All patients had a mutation in the protein tyrosine phosphatase catalytic domain of the PTPN11 gene; two unrelated patients had the p.Thr468Met mutation, while the family consisting of two affected individuals harboured the p.Thr279Cys mutation. Molecular analysis performed on hypertrophic nerve tissue did not disclose a second somatic hit in NF1, PTPN11, NF2 or SMARCB1 genes. Conclusions Neurogenic tumours and hypertrophic neuropathy are unusual complications of NSML and may be an under-recognised manifestation that would warrant surveillance. Our observation may also have implications for other disorders caused by RAS-pathway dysregulation.
Habenula
Benarroch, Eduardo E.

Neurology | September 2, 2015 | Volume: 85 | Issue: 11 | Pages: 992-1000

10.1212/wnl.0000000000001937 | PMID 26291286 Get It

Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma
Kumar, Shaji , Krishnan, Amrita , LaPlant, Betsy, Laumann, Kristina, Zimmerman, Todd M., Stockerl‐Goldstein, Keith , Birgin, Ann, Fiala, Mark A. , Duarte, Lupe, Maharaj, Michelle, Levy, Joan, Vij, Ravi , Buadi, Francis K. , Stockerl Goldstein, Keith, Roy, Vivek , Gertz, Morie A. , Fiala, Mark A , Stockerl-Goldstein, Keith

American Journal of Hematology | September 2, 2015 | Volume: 90 | Issue: 12 | Pages: 1106-1110

10.1002/ajh.24181 | PMID 26331432 Get It

Bendamustine is a multifunctional alkylating agent with single agent activity in myeloma. We designed the current phase 1/2 trial to determine the maximum tolerated doses (MTD) of bendamustine that can be safely combined with lenalidomide and dexamethasone and to assess the safety and efficacy of the combination. Patients with relapsed MM following at least 1 prior therapy, but no more than four lines of prior therapy and with measurable disease were enrolled. Bendamustine 75 mg/m2 given on days 1 and 2, lenalidomide 25 mg given days 1–21 and dexamethasone 40 mg on days 1, 8, 15, and 22, was the recommended Phase 2 dose. Seventy‐one patients were accrued: 21 on Phase 1 and 50 on Phase 2. The median age was 62.3 years; patients had a median of three prior lines of therapy (range 1–4), with over 70% of the patients having received prior lenalidomide, bortezomib, and/or peripheral blood stem cell transplant. Thirty‐four of 70 (49%) patients had a confirmed partial response or better, including 20 patients (29%) with a very good partial response or better. An additional 4 patients had a minor response, translating to an overall 55% clinical benefit rate. Grade 3 or higher toxicity was seen in 96% of patients, with ≥grade 3 hematologic in 94% and nonhematologic in 50%. The median progression free survival was 11.8 months and the median duration of response was 23 months. The combination of bendamustine, lenalidomide, and dexamethasone is very effective in relapsed multiple myeloma with high response rates and durable responses Am. J. Hematol. 90:1106–1110, 2015. © 2015 Wiley Periodicals, Inc.
Atrial fibrillation care improvement collaborative
Robelia, Paul M., Kopecky, Stephen L. , Robelia, Paul, Kopecky, Stephen, Thacher, Tom, Thacher, Tom D.

BMJ Quality Improvement Reports | September 2, 2015 | Volume: 4 | Issue: 1 | Pages: u208947.w3629

10.1136/bmjquality.u208947.w3629 | PMID 26734425 Get It

Abstract Atrial fibrillation (AF) is an increasingly common cardiac arrhythmia. Many patients with new onset or recurrent AF present to the emergency department and are subsequently admitted to the hospital and seen by cardiology specialists for follow up. In an attempt to address this high utilization of acute health care resources, reduce costs, and improve patient care, our institution instituted a collaborative project between the departments of emergency medicine, cardiology, family medicine, and primary care internal medicine. The project team oversaw development of a new emergency department AF order set, encouraged utilization of a new oral anticoagulant (dabigatran), improved the primary care follow up connection, and deployed a multimodal education plan for primary care providers. Between 2012 and 2014, these interventions resulted in a 17% reduction in total AF per member per month (PMPM) cost, a 28% reduction in AF PMPM inpatient cost, and a 24% reduction in inpatient admissions for AF.